Milkhaus reports Phase II/III data

Milkhaus (Boxford, Mass.) reported that an open-label cross-over study of its LDI-200 human chorionic gonadotropin showed efficacy and safety in patients with myelodysplastic syndrome (MDS), a bone ma...